Effective Collaboration - Team Research for Better Returns: Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Effective Collaboration - Team Research for Better Returns:

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Julius Wong	3/28/2024 3:33:27 PM
	of 8262

Exact Sciences gains after data for novel cancer screening test Mar. 28, 2024 3:13 PM ET By: Dulan Lokuwithana, SA News Editor Dr_Microbe/iStock via Getty Images Shares of Exact Sciences (NASDAQ: EXAS) gained Thursday after the cancer test maker announced data from a study for its Oncoguard Esophagus test, a non-endoscopic method to detect esophageal adenocarcinoma. Unlike invasive and costly screening methods used to detect esophageal adenocarcinoma, the most common form of esophageal cancer, the Oncoguard Esophagus test involves a string to deliver a swallowable capsule. The capsule's outer covering dissolves within the gastrointestinal tract, revealing a sponge collection device. The company said the trial indicated a 100% sensitivity (zero false positives) for Oncoguard in detecting esophageal adenocarcinoma and its precancerous lesion, Barrett's esophagus, with high-grade dysplasia. The trial enrolled 352 participants in the algorithm training set, and 125 in the test set, and its data was published in a peer-reviewed medical journal. Exact Sciences ( EXAS) added that patients tolerated the sample collection method well, which, it said, indicated suitability for use in doctors' offices. Exact Sciences ( EXAS) has partnered with Mayo Clinic to develop Oncoguard Esophagus.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next